With cardiovascular disease being the leading cause of morbidity and mortality worldwide,
effective and cost-efficient therapies to reduce cardiovascular risk are highly needed. Lipids …

To commemorate the auspicious occasion of the 30th anniversary of IPC, leading pioneers
in the field of cardioprotection gathered in Barcelona in May 2016 to review and discuss the …

Myocardial ischemia-reperfusion injury is a common condition in cardiovascular diseases,
and the mechanism of its occurrence involves multiple complex metabolic pathways and …

Melatonin is a pleiotropic hormone with several functions. It binds to specific receptors and
to a number of cytosolic proteins, activating a vast array of signalling pathways. Its potential …

The survivor activating factor enhancement (SAFE) pathway was discovered as an
alternative intrinsic pro-survival signaling pathway to the reperfusion injury salvage kinase …

Hyperlipidaemia is a well‐established risk factor for cardiovascular diseases and therefore,
many animal model have been developed to mimic the human abnormal elevation of blood …

High-density lipoprotein cholesterol (HDL-C) has been identified as a powerful independent
negative predictor of cardiovascular disease. The beneficial effect of HDL is largely …

Objective—The dyslipidemia of type 2 diabetes mellitus has multiple etiologies and impairs
lipoprotein functionality, thereby increasing risk for cardiovascular disease. High-density …

Protecting the heart after an acute coronary syndrome is a key therapeutic goal to support
cardiac recovery and prevent progression to heart failure. A potential strategy is to target …

Since the discovery of ischemic pre-and post-conditioning, more than 30 years ago, the
knowledge about the mechanisms and signaling pathways involved in these processes has …